Duncan Stewart
MD, FRCPC
Senior Scientist, Regenerative Medicine
Ottawa Hospital Research Institute
Professor, Dept of Medicine
Faculty of Medicine
Contact
613-737-8899
Research Administrative Assistant Adrienne Szalamin aszalamin@ohri.ca
Research Groups
Stewart Lab
Bio
Dr. Duncan J. Stewart is a pioneering Canadian cardiovascular researcher, recognized for his many important discoveries in blood vessel biology, as well as his dedication in translating these discoveries into benefits for patients and society by performing innovative gene and cell therapy clinical trials for heart failure, pulmonary hypertension and inflammatory lung diseases. After launching his career in academic cardiology at McGill University in Montreal, he moved to Toronto as Head of Cardiology at St. Michael’s Hospital (now Unity Health Toronto), and later became Director of the Division of Cardiology at the University of Toronto (U of T), and Executive Director of the McLaughlin Centre for Molecular Medicine. He was recruited to lead the Ottawa Hospital Research Institute (OHRI) in 2007.
Dr. Stewart has published more than 400 peer-reviewed manuscripts, and has received a number of distinctions and prizes, including U of T’s Dexter Man Chair of Cardiology and Research Achievement Award of the Department of Medicine, U of T, and the Research Achievement Award of the Canadian Cardiovascular Society. Throughout his career, Dr. Stewart has demonstrated leadership in bringing diverse groups of clinicians and scientists together to put Canada on the world stage for translational cardiovascular and regenerative medicine research.
As well as serving as CEO & Scientific Director of the OHRI and Executive Vice-President, Research at The Ottawa Hospital until 2024, Dr. Stewart is a Senior Scientist in OHRI's Regenerative Medicine Program and a Professor in the Department of Medicine at the University of Ottawa, and continues to lead a vibrant and productive research team. As Principal Investigator of the largest infrastructure grant in the history of the University of Ottawa, he will be playing a leadership role in the development of the new biotherapeutics manufacturing facility at The Ottawa Hospital’s new campus.
News
Publications
Study of angiogenic cell therapy for progressive pulmonary arterial hypertension: intervention with repeat dosing of eNOS-enhanced EPCs: the SAPPHIRE trial
2025-10-01 Go to publicationMapping disease-specific vascular cell populations responsible for obliterative arterial remodeling during development of pulmonary arterial hypertension
2025-08-25 Go to publicationSingle-cell microencapsulation improves lung retention of endothelial colony-forming cells after intravascular delivery and unmasks therapeutic benefit in severe pulmonary arterial hypertension
2025-06-01 Go to publicationSexual dimorphism in right ventricular adaptation to pressure overload involves differential angiogenic response
2025-03-01 Go to publication